Novavax: Extending delay between first and second dose should be ‘fine’

Professor Paul Heath said that separating the doses between the jab for more than three weeks – the interval studied in the trial – would “probably” still be effective

Lead research nurse Vash Deelchand gives a demonstration of the vaccine trial process as Kate Bingham, former chair of the Government’s Vaccine Taskforce, starts her Novavax trial (PA)

Delaying the second dose of the Novavax Covid-19 jab should be “fine”, an expert has said.

Professor Paul Heath, chief investigator for the Novavax trial in the UK, said that separating the doses between the jab for more than three weeks – the interval studied in the trial – would “probably” still be effective.